Passage Bio (PASG) 8-K Passage Bio Presents New Interim Clinical and Biomarker

Exhibit 99.2

Interim Safety, Biomarker, and Efficacy Data from Imagine - 1: A Phase 1/2 Open - Label, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Single Dose, ICM Administration of PBGM01 in Subjects with Type I (Early Onset) and Type IIa (Late Onset) Infantile GM1 Gangliosidosis (GM1) David Weinstein, MD, MMSc SVP, Clinical Development and Clinical Lead, Imagine - 1, Passage Bio, Inc. ICM= intra - cisterna magna .. American Society of Gene & Cell Therapy (ASGCT) 25 th Annual Meeting Wednesday, May 18, 2022

2 Notice • This presentation is about a research study aimed at assessing the safety and efficacy of an investigational treatment called PBGM01. ▪ Use of PBGM01 is not approved by any of the regulatory agencies for the treatment of GM1. ▪ The safety and efficacy of PBGM01 for the treatment of GM1 has not been established in humans. ▪ For additional information about the study, go to www.clinicaltrials.gov/ct2/show/NCT04713475. GM1=GM1 gangliosidosis.

3 GM1 Gangliosidosis • GLB1 gene mutation results in deficient β - Gal enzyme activity leading to intracellular ganglioside accumulation 1 • GM1 gangliosidosis is characterized by progressive neurological deterioration, progressive brain atrophy, cardiac and skeletal abnormalities 2 • Estimated incidence of 1 in 100,000 - 200,000 live births worldwide 1 • Currently, no effective medical treatment is available for the underlying GM1 gangliosidosis 3,4 Cooper GM1 patient Jaxson GM1 patient b - Gal= b - galactosidase; GM1=GM1 gangliosidosis. 1. Brunetti - Pierri N., Scaglia F. Mol Genet Metab. 2008;94(4):391 - 396. 2. Caciotti A., et al. Biochim Biophys Acta .. 2011;1812(7):782 - 790. 3. King KE, et al .. Mol Genet Meta Rep. 2020;25:100676. 4. Nicoli E - R, et al. Front. Genet. 2021; 12:734878.

4 Clinical Course of Infantile GM1 GM1 Gangliosidosis is a Continuum Disease Severity Residual Enzyme Activity 1,3 - 6 Imagine - 1 Trial will include Type I (Early Infantile) and Type IIa (Late Infantile) patients 7 Negligible ~1 - 5% ~3 – 10% Type I (Early Infantile) 1 • Onset <6 months 1 - 5 • Hypotonia 1 - 3 • Neurodegeneration 1,4,6 • Developmental regression 2 - 4,6 • Seizures 2 - 4,6 • Skeletal dysplasia 1,3,4 • Survival: <2 years 1 Type IIa (Late - Infantile) 3 • Onset 6 - 24 months 3,4 • Developmental plateau, followed by regression 2,3,5,6 • Impaired ambulation 2,4 - 5 • Impaired cognition 2,4 • Seizures 2 - 5 • Survival: 5 to 10 years 2,5 Type IIb (Juvenile) 3 • Onset 2 - 3 years 3,4 • Impaired ambulation 4,5 • Dysarthria 4,6 • Variable skeletal disease 4 - 6 • Decreased cognition 4,6 • Survival into 2nd decade 5 Type I/Early Infantile • No new developmental milestones reached after 3 - 6 months 5.8 Type IIa/Late - infantile • No new developmental milestone reached after 12 - 15 months 8 1. Brunetti - Pierri N., Scaglia F. Mol Genet Metab. 2008;94(4):391 - 396. 2. Jarnes JR, et al. Mol Genet Metab .. 2017;121(2):170 - 179. 3. Lang FM, et al. Mol Genet Metab. 2020;129(3):228 - 235. 4. Regier DS, et al. Am J Med Genet Part A .. 2016;170(3):634 - 644. 5. King KE, et al .. Mol Genet Meta Rep. 2020;25:100676. 6. Regier DS, Tifft CJ. Rothermel CE. GLB1 - related disorders. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews® [Internet]. University of Washington, Seattle; 2019:1993 - 2022. https://www.n cbi.nlm.nih.gov/books/NBK164500/ October 17, 2013. Updated April 22, 2021. Accessed March 7, 2022. 7. Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Subjects Wi th GM1 Gangliosidosis (Imagine - 1). ClinicalTrials.gov website https://www.clinicaltrials.gov/ct2/show/NCT04713475?term=passage+bio&draw=2&rank=3. January 19, 2021. Updated March 7, 2022. Acc essed March 7, 2022. 8. Nicoli E - R, et al. Front. Genet. 2021;12:734878.

5 Imagine - 1: Global Phase 1/2 Trial with PBGM01 Initial safety and biomarker data from Cohorts 2 & 3 expected in 2H 2022 Trial Design Phase 1/2, multi - center , open - label, dose escalation and confirmatory study Route of Administration Intra - cisterna magna (ICM) Vector AAVhu68 Duration Two years, with rollover into a separate long - term follow - up study Primary Endpoints • Safety and tolerability • Efficacy (confirmatory cohort) Regulatory Clearances and Designations • Received multiple global regulatory clearances • Received Orphan Drug, Rare Pediatric Disease and Fast Track designations by FDA and Orphan designation by EC COHORT 4 Early Infantile n = 2 D OSE 2 (1.1e11 GC/g)* D O S E 1 (3.3e10 GC/g)* Expansion Cohort Early Infantile n = 6 Expansion Cohort Late Infantile n = 6 COHORT 2 Late Infantile n = 2 COHORT 3 Early Infantile n = 2 COHORT 1 Late Infantile n = 2 60 days between subject enrollment IDMC review Recruiting Dosing complete * Genome copies per gram of estimated brain weight

6 Cohort 1: Baseline Patient Characteristics Patient 1 Patient 2 Diagnosis Late Onset Late Onset Dosing Cohort Low dose Low dose Gender Male Male Age at onset of symptoms (months) 14 12 Age at diagnosis (months) 2 30 Age at gene transfer (months) 15 31 DBS β - Gal activity * (nmol/mL/h) 0.0 0.2 Genotype p.R201C p.R201C p.R201C p.L578R Pre - existing vector nAbs – CSF † Negative Negative Pre - existing vector nAbs – Serum Positive Negative Developmental age on Bayley - III at baseline (months) 11 7 b - Gal= b - galactosidase; CSF=cerebrospinal fluid; DBS=dried blood spot; LLN=lower limit of normal; nAbs=neutralizing antibodies. * LLN: <5.0 nmol/mL/h. † Assay threshold titer value of 5.

7 Cohort 1 Safety & Tolerability No SAEs have occurred in either patient Reported AEs were mild - to - moderate; all moderate AEs resolved without intervention and were deemed non - treatment related No complications related to ICM administration were reported No changes in ALT or GGT occurred in either patient following vector administration No evidence of DRG toxicity clinically or on nerve conduction studies in either patient PBGM01 had a positive safety profile and was well tolerated at the interim analysis* *Patient 1 follow - up: 13 months; Patient 2 follow - up: 7 months. AEs=adverse events; ALT=alanine transaminase; DRG=dorsal root ganglion; gamma - glutamyl transferase; ICM= intra - cisterna magna; SAEs=serious adverse events.

8 Patient 1: Vineland - II Sustained improvement documented in all developmental areas through 12 - month assessments Parameter Baseline 3 months 6 months 9 months 12 months Patient Age 14 17 20 24 26 Motor Gross motor 13 14 21 22 21 Fine motor 12 14 16 19 22 Language Receptive language 12 14 25 34 32 Expressive language 8 12 16 19 18 Social Personal living skills 11 14 17 17 19 Interpersonal relationships 8 14 17 22 22 Play and leisure time 17 18 27 26 26 Overall Developmental Age (months) 12 16 21 23 24 8 13 18 23 28 33 38 13 15 17 19 21 23 25 27 Developmental Age (months) Chronological Age (months) Normal Fine motor Gross motor Receptive language Expressive language Personal living skills Interpersonal relationships Play and leisure time Overall T he Vineland - II is caretaker - assessed.

9 Developmental Gains for Patient 1 (Vineland - II) Baseline 12 - month Visit Gross motor Taking a few steps without support Observed jumping Balancing on 1 foot Climbing Stairs Fine motor Sometimes able to squeeze toy Opening door and locks Pours liquid without spilling Stacking 4 blocks Receptive language Never points to named body parts Never points to named objects in book Rarely follows 1 step command Follows 2 - step instructions Follows instructions heard 5 minutes before Points to items in book and body parts Expressive language Never uses “mama/dada” No words with meaning Uses names to address siblings Uses combination of words Creating simple sentences T he Vineland - II is caretaker - assessed.

10 Patient 1: Bayley - III Sustained improvement also directly observed in all developmental areas Parameter Baseline 3 months 6 months 12 months Patient Age 14 17 20 26 Motor Gross motor 13 14 15 15 Fine motor 11 16 16 17 Language Receptive language 10 16 16 18 Expressive language 10 14 15 19 Cognitive Cognition 13 16 19 19 Overall Developmental Age (months) 11.6 15.3 16.6 18 10 12 14 16 18 20 22 24 26 13 15 17 19 21 23 25 27 Developmental Age (months) Chronological Age (months) Normal Gross motor Fine motor Receptive language Expressive language Cognition Overall Patient 1 was subsequently found to have unrelated visual impairment that could have impacted the Bayley - III. ( Patient 1 recently began wearing glasses.) The Bayley scoring is based on direct observation by a neurodevelopmental specialist.

11 Patient 2: Vineland - II Continued improvement despite having severe developmental delay at baseline and prior history of regression Parameter Baseline 3 months 6 months Patient Age 31.6 34.5 37.6 Motor Gross motor 11 12 13 Fine motor 11 12 12 Language Receptive language 14 13 20 Expressive language 8 12 12 Social Personal living skills 16 16 17 Interpersonal relationships 13 21 21 Play and leisure time 12 12 23 Overall Developmental Age (months) 13 16 19 7 10 13 16 19 22 31 33 35 37 Developmental Age (months) Chronological Age (months) Normal Fine motor Gross motor Receptive language Expressive language Personal living skills Interpersonal relationships Play and leisure time Overall * *Not shown on graph because values are too high. T he Vineland - II is caretaker - assessed.

12 Developmental Gains for Patient 2 (Vineland - II) Baseline 6 - month Visit Gross motor Stand with support for 5 seconds Pulls to standing position Standing without support for 1 - 3 minutes Walks without support 2 - 3 steps Throws ball Fine motor Sometimes able to squeeze toy Transfers object from one hand to other Puts objects in container Removes objects in container Picks up small object with finger/thumb Receptive language Smiles upon hearing “yes” Stops when hearing no/stop Rarely follows 1 step command Follows 1 step command Points to 3 major body parts Expressive language Never uses “mama/dada” No words with meaning Pre - speech sounds Says mama/dada Waves goodbye Uses single words T he Vineland - II is caretaker - assessed.

13 Patient 2: Bayley - III Overall improvement observed for motor, language, and cognitive domains Parameter Baseline 3 months 6 months Patient Age 31.6 35 37.6 Motor Gross motor 10 12 11 Fine motor 7 9 7 Language Receptive language 4 9 11 Expressive language 7 7 6 Cognitive Cognition 8 9 13 Overall Developmental Age (months) 7.3 9.1 10.1 0 3 6 9 12 15 31 33 35 37 Developmental Age (months) Chronological Age (months) Normal Gross motor Fine motor Receptive language Expressive language Cognition Overall * *Not shown on graph due to the severe developmental delay. The Bayley scoring is based on direct observation by a neurodevelopmental specialist.

14 0 200 400 600 800 1000 Whole brain Cerebral cortex Cerebral white matter Cerebellum cortex Cerebellar white matter Baseline Month 6 Month 12 ↑ 15% ↑ 15% Patient 1: Change from Baseline at Month 12 (Age at gene transfer: 15 months) Patient 2: Change from Baseline at Month 6 (Age at gene transfer: 31 months) 35% inc 0 200 400 600 800 1000 Whole brain Cerebral cortex Cerebral white matter Cerebellum cortex Cerebellar white matter Baseline Month 6 ↑1% ↓~4% ↓~3% ↓~10% No change Cubic centimeters ↑27% ↓12% ↑35% 0 200 400 600 800 1000 Whole brain Cerebral cortex Cerebral white matter Cerebellum cortex Cerebellar white matter Baseline Month 6 Month 12 ↑ 15% ↑ 15% Cubic centimeters ↑27% ↓12% ↑35% Cohort 1 Volumetric MRI Data

15 Cohort 1 Interim Biomarker Data *Baseline reflects the average of two samples collected within 48 - hours of dosing. † Based on preliminary data from University of Pennsylvania’s ODC NHS study (NCT04041102). b - Gal= b - galactosidase; CSF=cerebrospinal fluid; NHS=natural history study. NHS patient value range 2.25 - 10 nmol/mL/3hr† NHS patient value range 0.30 - 1.81 nmol/mL/3hr† • CSF β - gal activity increased above levels seen in NHS following dosing and sustained at upper limit of NHS • Serum β - gal activity increased in both patients; however, over time, post - treatment β - gal activity for Patient 1 was above NHS patient values, while Patient 2 normalized to NHS patient values • CSF GM1 gangliosi des increased in Patient 1 but subsequently stabilized; data for Patient 2 fluctuated • Whole blood GM1 gangliosides in Patients 1 and 2 increased slightly thru ~50 d post - treatment, then trended downward slightly over time * Patient 1 Patient 2

16 Key Takeaways from Cohort 1 Interim Data Low dose PBGM01 was well - tolerated with demonstration of functional transgene expression and developmental improvement AEs =adverse events; ICM= intra - cisterna magna .. SAFETY Positive safety profile and well - tolerated with no serious AEs and no complications related to ICM injection CLINICAL STATUS Sustained and continual improvement across developmental areas on both the Vineland and Bayley scal es ADDITIONAL STUDIES Are needed to determine if biomarkers can predict outcomes and if treating early is critical to maximize the response

17 Acknowledgements Thank you to the patients, families, caregivers for their participation in this study. Thank you to the coordinators and site study staff who are instrumental in making this work happen. Co - authors Caroline A Hastings, UCSF Benioff Children’s Hospital Debra - Lynn Day - Salvatore, Saint Peter’s University Hospital Can Ficicioglu, Children’s Hospital of Philadelphia Chester B Whitley, University of Minnesota Michal Inbar - Feigenberg, The Hospital for Sick Children Geneviève Bernard, McGill University; McGill University Health Center Roberto Giugliani, Federal University of Rio Grande do Sul Julien Baruteau, Great Ormond Street Hospital for Children Fatih S Ezgü, Gazi University Sylvia Stockler, BC Children’s Hospital Jeanine R Jarnes, University of Minnesota Yan G. Ni, Pruthvi Nagilla, Victoria L Ballard, Thomas F Haws, Mark S. Forman, Passage Bio Michael H Gelb, University of Washington Michelle Miller, University of Pennsylvania Gene Therapy Program Vector is technology of The University of Pennsylvania (Gene Therapy Program). Imagine - 1 is funded by Passage Bio More information on the Imagine - 1 trial (NCT04713475) can be found at www.clinicaltrials.gov.